Expanding Imaging Capabilities - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Expanding Imaging Capabilities

Optos’ new Silverstone platform seeks to narrow the gap between visualization and structural insight in retinal imaging

  • June 1, 2026

  • 3 min

Share

Clinical Scorecard: Expanding Imaging Capabilities

At a Glance

CategoryDetail
Condition
Key MechanismsMultimodal imaging capabilities including ultra-widefield imaging, swept-source OCT, and nine imaging modalities.
Target Population
Care Setting

Key Highlights

  • Launch of Silverstone RGB system at AAO meeting in October 2025
  • Combines nine imaging modalities for comprehensive retinal assessment
  • Enhances color fidelity and deeper tissue penetration
  • Supports reliable longitudinal monitoring and informed clinical decision-making
  • Developed based on clinician feedback for improved workflow integration
  • Enables visualization of peripheral retina and deeper structures simultaneously

Guideline-Based Recommendations

Diagnosis

  • Utilize multimodal imaging, including RGB and SS-OCT, for comprehensive assessment of retinal pathology

Management

  • Incorporate Silverstone RGB for improved diagnosis and management of retinal conditions, utilizing its nine imaging modalities

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      Patients with retinal lesions requiring assessment

      Enhanced imaging capabilities may lead to improved outcomes

      Clinical Best Practices

      • Utilize the integrated SS-OCT for comprehensive evaluation of retinal layers
      • Ensure efficient workflow by leveraging the system's multimodal capabilities
      • Prioritize patient comfort and minimize burden during imaging
      • Incorporate clinician feedback in the use of the system for optimal outcomes

      Related Resources & Content

      Original Source(s)

      Expanding Imaging Capabilities

      • June 1, 2026

      Related Content

      Semaglutide Linked to NAION Risk

      A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

      ASRS President Reflects on a Year of Change

      As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

      Diabetic Retinal Disease Rates Narrow by Diabetes Type

      US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.